ANIP - Company ID 0001023024
The table below shows ANI PHARMACEUTICALS INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $58.38M | $34.99M | $18.27M | $21.42M | -$18.94M | $20.67M |
| Capital expenditure | $6.07M | $2.47M | $4.58M | $2.35M | $1.95M | $698.00K |
| Investing cash flow | -$11.32M | -$19.85M | $8.93M | -$2.35M | -$2.18M | -$737.00K |
| Dividends paid | $0.00 | $406.00K | $406.00K | $406.00K |
ANI PHARMACEUTICALS INC reported operating cash flow of $185.22M for fiscal year 2025. That is up 189.3% from $64.02M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $27.47M (FY 2016) to $185.22M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $405.00K |
| $0.00 |
| Stock buybacks | $19.75M | $10.00M | $8.66M | $3.55M | $1.12M | $348.00K |
| Financing cash flow | -$21.62M | -$9.91M | -$19.73M | -$4.55M | -$2.27M | -$2.73M |